Wellcome Trust
The Wellcome Trust and the UK Department of International Development (DFID) have funded a number of projects for the Zika virus and have recently confirmed funding for two projects investigating the persistence of immunity towards the yellow fever vaccine, both in adults and children.
Zika Virus
- Social and economic impacts of Zika virus infection in Brazil, Dr Hannah Kuper, LSHTM
- Care, health and stigma among families affected by the Congenital Zika Syndrome in Campina Grande, Brazil, Dr Debora Diniz, University of Brasilia
- Socio-cultural factors in Zika virus outcomes in Lusophone African countries. Dr Sharath Srinivasan, University of Cambridge
- Proposal for scale-up and Introduction of Wolbachia-infected Aedes mosquitos to decrease the spread of Zika virus in the Americas (together with the Bill and Melinda Gates Foundation, USAID and the Colombian government)
- Individual Patient Data (IPD) meta-analysis and prospective systematic review of ZIKV cohort studies of pregnant women, together with the WHO
- Persistence of Zika virus in body fluids of convalescents of Zika virus disease, together with Central Laboratories of Public Health Brazil, Ministry of Health Brazil, Walter Reed Army Institute of Research, the WHO
Yellow Fever
- Persistence of (humoral) immunity in children after Yellow Fever vaccination, Dr Cristina Domingo Carrasco , Robert Koch Institute
- Duration of immunity of the yellow fever vaccine in army recruits, participants of the study “17DD yellow fever vaccine. A double blind, randomized clinical trial of immunogenicity and safety on a dose-response study”, done in 2009. Dr Reinaldo de Menezes Martins, Institute of Technology on Immunobiologicals of Bio-Manguinhos/Fiocruz
Mosquito-borne Viruses: can we build on commonalities to pre-empt the future?
GloPID-R member The Wellcome Trust hosted this WHO conference in London, UK on October 5th to 7th 2016. The meeting covered a variety of topics concerning mosquito born viruses, including vaccines, vector control, medicines and blood products, diagnostics, regulatory issues, and yellow fever. An executive summary is now available and an official synopsis of this meeting will be published in early 2017.
